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Etanercepta b s t r a c t
Background: Interleukin-6 (IL-6) plays a significant role in pathogenesis of rheumatoid arthritis (RA), but
its single nucleotide polymorphisms (SNPs), as well as therapy may modulate such role.
Objectives: It was aimed to determine gene expression and six SNPs (rs1800796 C/G, rs7802307 A/C/T,
rs7802308 A/T, rs36215814 A/G, rs184229712 A/G and rs867254801 C/G) of IL6 in etanercept-treated
Iraqi Arab RA patients.
Materials and methods: Fifty-one RA patients and 45 controls were enrolled, and the determinations were
carried out by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Sanger’s DNA
sequencing. Disease activity and laboratory markers were considered in these evaluations, which were
the first presentation in Iraqi patients.
Results: The DCt mean of IL6 mRNA showed a significant increase in RA patients compared to control
(9.084 ± 0.964 vs. 6.780 ± 2.240; p = 0.0001). In terms of a relative expression, the 2DDCt means showed
no significant variations between subgroups of patients distributed by clinical and laboratory findings,
with the exception of C-reactive protein (CRP). CRP-positive patients showed a lower mean compared
to CRP-negative patients (0.201 ± 0.109 vs. 0.312 ± 0.131; p = 0.001). Distributing patients by gender
and duration of disease also revealed significant variations between male and female patients. With
respect to SNPs, allele and genotype frequencies of four SNPs (rs1800796, rs7802307, rs184229712
and rs867254801) showed variations between patients and controls, while no differences were reported
for rs7802308 and rs36215814 SNPs. In addition, IL6 gene expression was significantly influenced by two
SNP genotypes (rs36215814 GA and rs184229712 AG) compared to the corresponding GG genotypes.
Conclusion: Gene expression of IL6 was down-regulated in RA patients, especially CRP-negative patients.
Moreover, four SNPs of such cytokine may have a role in RA risk.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is a multifactorial and a heteroge-
neous autoimmune disease. Both genetic and environmentalfactors contribute to its etiology and pathogenesis.1 Environment-
gene interactions in RA are suggested to promote the immune
system of patients to loss tolerance to self-proteins, especially those
that contain a citrullinated peptide, which is produced by a post-
translational modification.2 This is followed by a localized inflam-
matory response that occurs in joints by mechanisms that may
involve different humoral and cellular immune responses, in which
microvascular and tissue-specific immunological components are
involved. Initiation and perpetuation of synovitis is the outcome
of these reactions. This is evident by a characterized hyperplasia
in the synovium of RA patients.3 Thus, innate and adaptive immune
responses are dysregulated in RA patients, and cytokines are a
major player in mediating these responses.
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are probably responsible for inflammatory reactions and joint
destruction that occur during the course of disease. One these
cytokines is interleukin-6 (IL-6), which is a 26 kDa glycoprotein
produced by various cells; including T and B cells, monocytes,
fibroblasts, osteoblasts, keratinocytes, endothelial cells and mesan-
gial cells. Immunologically, IL-6 is a pleiotropic cytokine that has
both pro- and anti-inflammatory properties and plays multiple
roles in adaptive immunity.4 In RA patients, IL-6 showed increased
levels in serum and synovial fluid, and such increase was positively
correlated with disease severity and joint destruction.5 Synovitis is
also promoted by IL-6 via inducing neovascularization, in which
vascular endothelial growth factors mediate the proliferation and
outcomes in inflammatory cell infiltration and hyperplasia of syn-
ovium.6 Further evidence suggests that IL-6 is a mediator of joint
erosion and causes bone resorption by inducing the formation of
osteoclasts. Cartilage degeneration is also caused by IL-6 via matrix
metalloproteinases produced by synovial cells and chondrocytes.7
IL-6 is also responsible for mediating many of the inflammatory
manifestations in RA patients; for instance, it induces hepatocytes
to produce C-reactive protein (CRP).4
Tumor necrosis factor-a (TNF-a) is a further cytokine involved
in pathogenesis of RA. In a clinical practice, TNF-a has been a target
for immunotherapy, and etanercept is one of these therapies.
Etanercept-treated RA patients have shown a more rapid improve-
ment in disease activity and a slower rate of radiographic progres-
sion than methotrexate-treated patients.8 However, it has also
been reported that etanercept decreases IL-6 levels in RA patients.9
The diverse roles played by IL-6 in RA pathogenesis and severity
have been further explored in terms of its single nucleotide poly-
morphisms (SNPs). Some studies examined the association
between IL6-174 SNP (G/C) and RA susceptibility and activity in dif-
ferent ethnic populations, but the results were subjected to
ethnicity-associated variations and diverse findings were
reported.10–12 However, a meta-analysis showed that this SNP is
significantly associated with an increased RA risk in an overall pop-
ulation analysis, but it was more pronounced in Asians.13 A further
SNP (572 G/C) of IL6 gene has also been associated with an
increased RA risk in Chinese Hans patients. The SNP was suggested
to exert an influence on the transcription rate of IL-6, and may
influence its serum level in RA patients.14 Additional findings indi-
cated that IL6-174 SNP is associated with severe joint radiographic
damage, while IL6-572 showed no such association.15
Accordingly, this study was conducted to assess gene expres-
sion and six SNPs (rs1800796 C/G, rs7802307 A/C/T, rs7802308
A/T, rs36215814 A/G, rs184229712 A/G and rs867254801 C/G) of
IL-6 in etanercept-treated RA Iraqi Arab patients, with some
emphases on disease activity, as well as clinical and laboratory
markers of disease.
2. Materials and methods
2.1. Patients
The present case-control study was approved by the ethics
committee at the Ministry of Health in Iraq. Fifty-one Iraqi Arab
RA patients were enrolled during the period November 2015 – June
2016. Their age range was 20–63 years. The diagnosis was made by
the consultant medical staff at the Rheumatology Unit (Baghdad
Teaching Hospital). It was based on the revised diagnostic criteria
established by the American College of Rheumatology (ACR), 2010.
They included tender and swollen joint counts, erythrocyte sedi-
mentation rate (ESR), CRP, anti-cyclic citrullinated protein (ACCP)
antibodies, rheumatoid factors (RFs) and symptom duration.16
The RA patients were under therapy for a period of 3–5 years. It
was a single weekly subcutaneous dose of 25 mg of etanercept.The patients were sub-grouped according to gender, duration of
disease (<5, 5–10 and >10 years), and laboratory markers of RA.
The latter included RFs, CRP (positive and negative) and ACCP anti-
bodies (weak, 20.0–39.9; moderate, 40.0–59.9; and strong positive,
60.0 U/ml). A further sub-grouping of patients was based on ESR-
disease activity score (DAS)-28.17
In addition to patients, 45 apparently healthy individuals (con-
trols), matched patients for ethnicity (Iraqi Arabs), gender and age,
were also enrolled in the study. Their age range was 25–52 years.
The control individuals were also assessed for ESR, RFs and CRP.2.2. Gene expression of IL6
The blood was collected from RA patients in EDTA tubes during
their visit to the Rheumatology Unit to take their subcutaneous
dose of etanercept (after seven days of previous dose and an hour
before the next dose). The expression of IL6 gene was determined
by the reverse transcription quantitative polymerase chain reac-
tion (RT-qPCR) method after isolation of total RNA. A ready-to-
use reagent (TRIzolTM LS Reagent; Thermo Fischer Scientific;
USA) was used to isolate total RNA, and the instructions of manu-
facturer were followed.
The isolated RNA was reversely transcribed to cDNA using the
GoTaq 1-Step RT-qPCR System kit (Promega, USA). Forward (50-
AATTCGGTACATCCTCGACGG-30) and reverse (50-GGTTGTTTTCTGC
CAGTGCC-30) oligonucleotide primers of IL6 gene were adopted
from a previous study, in which the forward and reverse primers
of the housekeeping gene GAPDH (reference gene: glyceraldehyde-
3-phosphate dehydrogenase) were also given.18
The reaction mix was adjusted to a final volume of 20 ll as sug-
gested by the manufacturer, and included: 10 ll GoTaq qPCR
Master Mix (1X), 0.5 ll GoScriptTM RT Mix for 1-Step RT-qPCR
(1X), 2 ll of each primer (10 mM), 5 ll RNA (62–110 ng/ll), and
0.5 ll nuclease-free water. The mix was transferred to a real-
time thermocycler (SaCycler; Sacace, Italy), which was pro-
grammed for the following optimized cycles: cDNA synthesis
for15 minutes at 37 C (one cycle), initial denaturation for 5 min
at 95 C (one cycle), 40 cycles of denaturation (30 s at 95 C),
annealing (30 s at 60 C) and extension (30 s at 72 C), and finally
one cycle of melt curve at 65–90 C.
The expression was given as 2DDCt, which represents the
Relative Fold Change. Therefore, the results were expressed as a
fold change in the expression level of a target gene that was nor-
malized to endogenous control (housekeeping gene) and relative
to a calibrator, which is the target gene in control subjects.192.3. IL6 gene SNPs
The Genomic DNA was extracted from EDTA blood using
ReliaPrepTM Blood gDNA Miniprep System (Promega Corporation,
USA), and after assessing purity and concentration, it was sub-
jected to PCR amplification. Forward (50-GGAGTCACACACTC
CACCT-30) and reverse (50-CTGATTGGAAACCTTATTAAG-30) primers
of IL6 were adopted from a previous study.12 The PCR reaction was
performed in a final volume of 25 ml, which included 12.5 ml GoTaq
green Master mix, 0.75 ll of each primer (10 lM), 2 ml DNA sample
(50 ng) and 9 ml nuclease-free distilled water. The PCR conditions
were initial denaturation at 95 C for 5 min (one cycle), followed
by 35 cycles of denaturation at 95 C (30 s), annealing at 60 C
(30 s) and extension at 72 C (30 s), followed by a final extension
at 72 C for 7 min. The amplified PCR fragments were subjected
to Sanger’s sequencing using ABI3730XL automated DNA sequen-
cer (Macrogen Corporation – Korea). The IL6 gene SNPs
(rs1800796, rs7802307, rs7802308, rs36215814, rs184229712
and rs867254801) and their genotypes were revealed by the
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sequences in the Gene Bank.
2.4. Statistical analyses
Data of gene expression were given as mean ± standard devia-
tion (SD), and significant differences between means were assessed
by ANOVA (Analysis of Variance) followed by LSD (Least Significant
Difference) or multiple range Duncan test. A probability that equals
or less than 0.05 was considered significant. These analyses were
carried out by using the statistical package SPSS version 13.0.
Allele frequencies of IL6 SNPs were estimated by the direct gene
counting method, while a significant departure from Hardy-
Weinberg equilibrium (HWE) was estimated using HWE calculator
for two alleles. Significant differences between the observed and
expected genotype frequencies were assessed by Pearson’s Chi-
square test.20
Allele and genotypes of IL6 SNPs were given as percentage fre-
quencies, and significant differences between their distributions in
RA patients and controls were assessed by Fisher’s exact probabil-
ity (p), which was corrected for the number of comparisons made
at each locus (Bonferroni Correction). In addition, odds ratio (OR)
and its 95% confidence interval were also estimated to define the
association between allele or genotype and RA. The WINPEPI pack-
age version 11.36 was used to carry out these estimations.Table 2
The DCt means of IL6 mRNA in rheumatoid arthritis patients and controls.
Groups Number DCt (Mean ± SD) p-value
Total Patients 51 9.084 ± 0.964 0.0001
Controls 45 6.780 ± 2.240
Males Patients 22 9.181 ± 1.088 0.013
Controls 15 7.793 ± 0.608
Females Patients 29 9.017 ± 0.888 0.0001
Controls 30 6.273 ± 2.574
SD: Standard deviation.3. Results
3.1. Basic characteristics of patients and controls
Clinical and laboratory characteristics (gender, age, duration of
disease, DAS-28, RFs, CRP, ACCP antibodies and ESR) of RA patients
and control are given in Table 1. It worth to mention, that control
subjects were sero-negative for RFs and CRP, and their ESR mean
was within the normal range (6.3 ± 2.9 mm/hour).
3.2. Gene expression of IL6
The DCt of IL6 mRNA showed a significant increased mean in
total, male and female RA patients compared to the corresponding
means in controls (Table 2). However, when RA patients
distributed according to their clinical and laboratory findings, noTable 1





Gender: N (%) Male 22 (43.1) 15 (33.3)
Female 29 (56.9) 30 (66.7)
Age (Mean ± SD; years) 44.9 ± 10.7 41.3 ± 8.7
Duration of disease: N (%) <5 years 14 (27.5) –
5–10 years 26 (51.0) –
>10 years 11 (21.5) –
DAS-28: N (%) Low 2 (3.9) –
Medium 29 (56.9) –
High 20 (39.2) –
RF: N (%) Positive 27 (52.9) 0.0
Negative 24 (47.1) 100.0
CRP: N (%) Positive 33 (64.7) 0.0
Negative 18 (35.3) 100.0
ACCP: N (%) Weak positive 24 (47.1) NT
Moderate positive 8 (15.7) NT
Strong positive 19 (37.2) NT
ESR (Mean ± SD; mm/hour) 50.9 ± 29.5 6.3 ± 2.9
SD: Standard deviation, N: absolute number, DAS-28: Diseases activity score-28, RF:
Rheumatoid factors, ACCP: Anti-cyclic citrullinated peptide, ESR: Erythrocyte
sedimentation rate, NT: Not tested.significant variation between the 2DDCt means of their subgroups
was observed, with the exception of CRP. Patients sero-positive for
CRP showed a lower mean of 2DDCt compared to sero-negative
patients (Table 3). In addition, presenting 2DDCt means in male
and female patients distributed by duration of disease revealed
significant differences. Female patients at durations of disease <5
and >10 years showed an increased mean of IL6 mRNA folding
expression compared to male patients. For the disease duration
5–10 years, an opposite observation was made; male patients
showed a higher mean than female patients (Table 4).
3.3. IL6 gene SNPs
Six SNPs with polymorphic frequencies (rs1800796 C/G,
rs7802307 A/C/T, rs7802308 A/T, rs36215814 A/G, rs184229712
A/G and rs867254801 C/G) were assigned in the DNA sequence
of the PCR amplified region (527 bp) (Fig. 1). The genotype fre-
quencies of these SNPs were in a good agreement with HWE in
RA patients and controls, as there were no significant differences
between the observed and expected genotype frequencies. How-
ever, comparing patients to controls revealed variations in four
SNPs only (Table 5).
The first SNP was rs1800796 (C/G). It was observed with three
genotypes in RA patients (CC, CG and GG) that had frequencies of
92.1, 5.9 and 2.0%, respectively. The corresponding C and G allele
frequencies were 95.1 and 4.9%, respectively. Among controls, only
the wild type genotype (CC) was found (100%). Although the
mutant allele G was recorded in 4.9% of RA patients and none of
the controls, no significant variation was observed between the
two groups.Table 3




Gender Male 22 0.238 ± 0.154 NS
Female 29 0.242 ± 0.107
Duration of
disease
<5 years 14 0.191 ± 0.067 NS
5–10 years 26 0.257 ± 0.117
>10 years 11 0.262 ± 0.189
DAS-28 Low 2 0.172 ± 0.098 NS
Medium 29 0.229 ± 0.113
High 20 0.263 ± 0.152
RFs Positive 27 0.219 ± 0.119 NS
Negative 24 0.263 ± 0.132
CRP Positive 33 0.201 ± 0.109 0.001
Negative 18 0.312 ± 0.131
ACCP Weak positive 24 0.260 ± 0.146 NS
Moderate positive 8 0.198 ± 0.110
Strong positive 19 0.232 ± 0.113
SD: Standard deviationDAS-28: Diseases activity score-28, RFs: Rheumatoid factors,
CRP: C-reactive protein, ACCP: Anti-cyclic citrullinated peptide, NS: Not significant.
Table 4
Expression fold (2DDCt) of IL6 mRNA in rheumatoid arthritis patients distributed by
duration of disease and gender.
Duration of disease Number 2DDCt (Mean ± SD) p-value
<5 years Males 6 0.162 ± 0.041 0.016
Females 8 0.212 ± 0.076
5–10 years Males 9 0.319 ± 0.120 0.05
Females 17 0.225 ± 0.107
>10 years Males 7 0.199 ± 0.195 0.008
Females 4 0.372 ± 0.124
SD: Standard deviation.
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a significant increased frequency in patients compared to controls
(62.8 vs. 33.3%; p = 0.004; OR = 3.37; 95% CI = 1.47–7.74), and the
difference remained significant after the correction probability
(pc = 0.02). Such difference was more presented when the compar-
ison was based on allele frequencies. The T allele showed a cor-
rected significant decreased frequency in patients compared to
controls (23.5 vs. 43.3%; pc = 0.015), while A allele showed aFig. 1. DNA sequence chromatogram of six IL6 gene SNPs (rs1800796 C/G, rs7802307
showing the heterozygous genotype of each SNP in rheumatoid arthritis patients (RA_IL_corrected significant increased frequency (76.5 vs. 56.7%;
pc = 0.015). These findings suggest that T is a protective allele
(OR = 0.40; 95% C.I. = 0.22–0.74), while A is a predisposing allele
(OR = 2.49; 95% C.I. = 1.34–4.60).
The third SNP was rs184229712 (A/G), in which the homozy-
gous genotype frequency of mutant allele (GG) showed a corrected
significant increased frequency in patients compared to control
(45.1vs. 26.7%; pc = 0.003; OR = 5.34; 95% C.I. = 1.94–14.66). In
terms of allele frequencies, the wild A allele showed a corrected
significant decreased frequency in patients compared to controls
(23.4 vs. 56.7%; pc = 0.0025), while the mutant G allele showed a
corrected significant increased frequency (67.6vs. 43.3%;
pc = 0.0025). These findings suggest that A is a protective allele
(OR = 0.37; 95% C.I. = 0.20–0.66), while G is a predisposing allele
(OR = 2.73; 95% C.I. = 1.52–4.91).
The fourth SNP was rs867254801 (C/G). It was observed with
three genotypes in RA patients (AA, AG and GG) and two genotypes
in controls (AA and AG), which were correspondent to two alleles
(A and G). Allele A showed a corrected significant decreased fre-
quency in RA patients (63.7 vs. 80.0%; OR = 0.44; 95% C.I. = 0.23–
0.84; pc = 0.048), while G allele showed a corrected significantA/C/T, rs7802308 A/T, rs36215814 A/G, rs184229712 A/G and rs867254801 C/G)
6). The reference sequences of SNPs are denoted with A, B, C, D, E and F, respectively.
Table 5
Allele and genotype frequencies of IL6 gene single nucleotide polymorphisms in rheumatoid arthritis patients and control.
IL6 SNP allele and genotype Percentage OR 95% CI p-value Bonferroni Correction
Patients (No. = 51) Controls (No. = 45)
rs1800796
C 95.1 100.0 – – NS NS
G 4.9 ND – – NS NS
CC 92.1 100.0 – – NS NS
CG 5.9 ND – – NS NS
GG 2.0 ND – – NS NS
rs7802307
A 76.5 56.7 2.49 1.34–4.60 0.003 0.015
T 23.5 43.3 0.40 0.22–0.74 0.003 0.015
AA 62.8 33.3 3.37 1.47–7.74 0.004 0.002
AT 27.5 46.7 0.43 0.19–1.00 0.04 NS
TT 9.8 20.0 0.43 0.14–1.39 NS NS
rs7802308
A 52.0 57.0 0.83 0.47–1.46 NS NS
T 48.0 43.0 1.21 0.69–2.13 NS NS
AA 27.5 33.3 0.76 0.32–1.80 NS NS
AT 49.0 46.7 1.10 0.50–2.43 NS NS
TT 23.5 20.0 1.23 0.47–3.23 NS NS
rs36215814
G 92.2 86.7 1.81 0.71–4.62 NS NS
A 7.8 13.3 0.55 0.22–1.41 NS NS
GG 84.3 73.3 1.95 0.72–5.27 NS NS
GA 15.7 26.7 0.51 0.19–1.38 NS NS
AA ND ND – – NS NS
rs184229712
A 32.4 56.7 0.37 0.20–0.66 0.0005 0.0025
G 67.6 43.3 2.73 1.52–4.91 0.0005 0.0025
AA 9.8 26.7 0.30 0.10–0.92 0.029 NS
AG 45.1 60.0 0.55 0.25–1.22 NS NS
GG 45.1 13.3 5.34 1.94–14.66 0.0006 0.003
rs867254801
G 63.7 80.0 0.44 0.23–0.84 0.0095 0.048
A 36.3 20.0 2.28 1.19–4.37 0.0095 0.048
GG 35.3 60.0 0.36 0.16–0.83 0.013 NS
GA 56.9 40.0 1.98 0.88–4.42 NS NS
AA 7.8 ND – – NS NS
SNP: Single nucleotide polymorphism, OR: Odds ratio; CI: Confidence interval; NS: Not significant; ND: Not detected.
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C.I. = 1.19–4.37; pc = 0.048).
Finally, allele and genotype frequencies of rs7802308 (A/T) and
rs36215814 (A/G) SNPs showed no significant variations between
patients and controls.
3.4. Impact of genotypes on IL6 expression
Out of the six investigated SNPs, two SNP genotypes impacted
the expression of IL6 gene in RA patients. The GA genotype of
rs36215814 SNP was associated with a significant increased mean
of 2DDCt compared to GG genotype. The second SNP was
rs184229712, in which the 2DDCt mean was significantly
increased in AG genotype compared to GG genotype (Table 6).Table 6
Impact of single nucleotide polymorphism genotypes on IL6 expression in rheumatoid art
IL6 SNP 2DDCt (Mean ± SD)
rs1800796 CC (0.242 ± 0.128)A
rs7802307 AA (0.235 ± 0.125)A
rs7802308 AA (0.196 ± 0.082)A
rs36215814 GG (0.216 ± 0.108)B
rs184229712 AA (0.225 ± 0.116)AB
rs867254801 GG (0.213 ± 0.119)A
Similar superscript letters represent no significant difference between means of each
between means (horizontal comparison; multiple range Duncan test). SNP: Single nucle4. Discussion
The DCt of IL6 mRNA showed a significant increased mean in
total RA patients compared to controls, and a similar observation
was made in male and female patients. Such findings suggest that
IL6 gene expression was down-regulated in RA patients. Assessing
the 2DDCt mean revealed that the relative expression was below
one. When the clinical and laboratory characteristics of RA patients
were considered (duration of disease, DAS-28, RFs, CRP and ACCP
antibodies), no significant variation was observed between the
2DDCt means of their subgroups, with the exception of CRP.
Patients sero-positive for CRP showed a significantly lower mean
of 2DDCt compared to sero-negative patients. These results are
not consistent with the general functional role of IL-6 inhritis patients.
CG (0.228 ± 0.140)A GG (0.137)
AT (0.256 ± 0.132)A TT (0.224 ± 0.125)A
AT (0.251 ± 147)A TT (0.266 ± 0.121)A
GA (0.366 ± 0.155)A AA (Not detected)
AG (0.273 ± 0.136)A GG (0.154 ± 0.092)B
GA (0.246 ± 0.136)A AA (0.309 ± 0.061)A
SNP, while different superscript letter represent significant difference (p  0.05)
otide polymorphism, SD: Standard deviation.
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and synovial fluid of RA patients, and such increase was correlated
with RA activity. This statement further confirms the importance of
conducting a correlation test between the expression fold of IL6
gene and the DAS-28. Such test revealed a gradual increased
expression as RA patients progressed from low to high DAS-28,
but the difference was no significant. It has further been docu-
mented that this cytokine is connected with local inflammation
and joint destruction in RA patients.21 IL-6 also showed an
increased expression in the inflamed synovial tissue of RA patients,
and influenced the functions of macrophages and T and B lympho-
cytes and osteoclasts.22 The pathological role of IL-6 was confirmed
in mouse model of collagen-induced arthritis (CIA), and anti-IL-6R
treatment was associated with amelioration of RA histopathologi-
cal features (inflammatory synovitis and joint erosions) in these
animals. Gene deficiency and blockade of IL-6 activity also reduced
severity of arthritis in mouse model of RA.23,24
The discrepancy between the present results and the above
mentioned studies might be ascribed to the therapy status of RA
patients who were under the anti-TNF therapy etanercept, but
such conclusion is limited because untreated patients were not
included in the study. However, TNF inhibitors have been shown
to reduce serum levels of IL-6.25 It has been documented further
that a pretreatment with etanercept in HIV patients may blunt
activation of IL-6 and CRP expression induced by recombinant
human IL-2.26 In a further investigation, the influence of TNF-a
on inflammation in CCl4-induced rats treated with etanercept
was studied. It was found that the expression of IL-6 was decreased
as the concentration of TNF-a was blocked by increased doses of
etanercept.27 These findings clearly suggest the pathologic role of
IL-6 in etiology of RA.
Such pathogenic-etiological role of IL-6 can be further under-
stood when the gene polymorphism of such cytokine is deter-
mined. The present results demonstrated that GG genotype of IL6
SNP rs184229712 (A/G) showed a significant increased frequency
in RA patients compared to controls, and the associated OR was
5.34. Such difference was more pronounced when the comparison
was based on allele frequencies, and G allele showed a corrected
significant increased frequency (susceptibility allele), while A allele
frequency was significantly decreased (protective allele). However,
such SNP has not been investigated in RA, but other SNPs in vicin-
ity of rs184229712 SNP has been studied and different results were
reported. IL6-174 (G/C) is among these SNPs, and studies have sug-
gested its role in RA susceptibility and activity in RA patients of dif-
ferent ethnicities, and different results were reported. Such
differences were related to the ethnicity of patients under investi-
gation.10–12 This SNP has also been subjected to a meta-analysis of
different studies (European and Asian in origin), and its effect on
risk of RA was suggested, especially in Asian patients.13 Another
IL6 SNP (IL6-572: G/C) has also been investigated and its association
with RA susceptibility or severity has been suggested in patients of
different ethnicities.14,15
The AG genotype of IL6 rs184229712 SNP was observed to be
significantly associated with an increased expression of IL6 gene
compared to GG genotype; therefore, it is suggested that such
SNP may influence the gene expression of IL6 and subsequently
its serum level in RA patients. The IL6-174 and IL6-572 SNPs have also
been suggested to exert an influence on the transcription rate of IL-
6 protein, and may influence IL-6 serum level in RA patients.145. Conclusions
A down-regulation of IL6 gene expression was suggested in RA
patients, and it was possibly due to the effects of the anti-TNF ther-
apy etanercept. Moreover, such expression was influenced by thegenotypes of two IL6 SNPs (rs36215814 and rs184229712). An
association between four IL6 SNPs (rs1800796, rs7802307,
rs184229712 and rs867254801) and risk of RA is also suggested
in Iraqi patients. However, the results could be more informative
if two other groups of patients were investigated; untreated
patients and patients under other types of therapies. The latter
subgrouping of patients represents a limitation of present study.
Moreover, further work in relation to other specific biological ther-
apies (for instance, tocilizumab) versus the standard therapy
methotrexate with follow up of patients can illustrate a better pro-
file about the role of IL-6 in RA pathology and etiology.
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